Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Total Liabilities (2019 - 2025)

Historic Total Liabilities for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $155.8 million.

  • Kymera Therapeutics' Total Liabilities rose 977.65% to $155.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $155.8 million, marking a year-over-year increase of 977.65%. This contributed to the annual value of $142.4 million for FY2024, which is 2122.49% down from last year.
  • According to the latest figures from Q3 2025, Kymera Therapeutics' Total Liabilities is $155.8 million, which was up 977.65% from $159.6 million recorded in Q2 2025.
  • Kymera Therapeutics' 5-year Total Liabilities high stood at $189.3 million for Q1 2021, and its period low was $113.0 million during Q4 2022.
  • In the last 5 years, Kymera Therapeutics' Total Liabilities had a median value of $146.5 million in 2023 and averaged $149.2 million.
  • In the last 5 years, Kymera Therapeutics' Total Liabilities soared by 10181.12% in 2021 and then tumbled by 2903.52% in 2022.
  • Over the past 5 years, Kymera Therapeutics' Total Liabilities (Quarter) stood at $146.3 million in 2021, then fell by 22.76% to $113.0 million in 2022, then skyrocketed by 60.01% to $180.8 million in 2023, then decreased by 21.22% to $142.4 million in 2024, then grew by 9.39% to $155.8 million in 2025.
  • Its Total Liabilities was $155.8 million in Q3 2025, compared to $159.6 million in Q2 2025 and $132.1 million in Q1 2025.